New website and branding for Evgen Pharma

Preparing a biopharmaceutical company for an Initial Public Offering (IPO) on AIM (the Alternative Investment Market)

The Brief

Evgen is a UK-based biopharmaceutical company that is taking a novel approach to developing a new anti-cancer drug. Evgen’s lead compound is a pharmaceutical drug called Sulforadex® that retards tumour growth and is a potent anticancer stem cell agent – making it a very attractive asset for big pharma or biotech going forward.

In 2014, the management team at Evgen were preparing the company for an Initial Public Offering (IPO) on AIM (the Alternative Investment Market) and were looking to re-position the brand and refresh its visual identity.

The Approach

Evgen Pharma was looking to engage with both existing funders and partners as well as potential new investors.

Evgen's previous identity was green which the organisation was looking to move away from because of its connotations of plants - whilst the active component of the drug originates from plants, the drug form is very different so they did not want to misrepresent themselves in any way. The values that Evgen wished to get across in the re-brand were Corporate, Clinical, Clean, Valuable, Safe, Secure and Reliable.

Once created, the visual identity was applied to a number of offline and online materials including a new website created by HMA.

When considering the graphical element of the logo, this was inspired by the structure of Sulforadex®.

The Result

The result is a clean, professional brand, visual identity and suite of marketing materials. The website provides a platform for Evgen to tell its story, publicise developments and engage with its target audiences.

Visit the Evgen site

Evgen Pharma PLC

Evgen floated on the London Alternative Investments Market (AIM) on the 21st October 2015 with a market capitalisation at the placing price of approximately £27million

AIM listed Evgen